Asthma impacts on work productivity and daily activities in employed patients who are symptomatic despite background therapy: a multi-national survey
23 February 2017 (online)
This multi-national survey aimed to increase understanding of the impact of symptomatic asthma on work productivity and daily activities in adults receiving maintenance therapy.
The Work Productivity and Activity Impairment Specific Health Problem questionnaire is an internationally recognised and validated, six-question, patient-administered, quantitative assessment of absenteeism, presenteeism (reduced on-the-job effectiveness) and daily activity impairment attributable to a specific health problem, during the past 7 days. Adults with asthma, diagnosed by a healthcare professional, in full-/part-time employment and confirmed as symptomatic, despite receiving long-term asthma control medication, were identified from a consumer panel using initial screening questions and surveyed via an internet questionnaire.
Of 6140 participants, 1598 fulfilled screening criteria and completed the survey: Brazil, n = 200; Canada, n = 200; Germany, n = 293; Japan, n = 305; Spain, n = 300; UK, n = 300. Mean scores at respondent level were: absenteeism, 9.1%; presenteeism, 31.5%; overall work impairment, 35.7%; non-work activity impairment, 38.1%. On average, 74% of participants reported some reduction (question score ≥1/10) in work productivity, while 42% and 51% of participants reported a prominent reduction (question score ≥4/10) in work productivity and ability to perform daily activities, respectively, because of asthma. Respondents reported missing, on average, 3 working hours per week because of asthma symptoms. The majority of participants indicated that asthma at work affects them physically and mentally; only 13% reported no impact.
For a substantial proportion of adult patients in employment with symptomatic asthma despite long-term maintenance medication, asthma has a large negative impact on work productivity and daily activity.
Declaration of interest:
Survey funding: Boehringer Ingelheim. Editorial assistance: Complete HealthVizion.
Content already presented at IPCRG congress 2016